Section Arrow
Quote
LTGO.NASDAQ
- Latigo Biotherapeutics, Inc.
Quotes are at least 15-min delayed:2026/09/24 00:07 EDT
Regular Hours
Last
 19.97
-0.85 (-4.08%)
Day High 
20.79 
Prev. Close
20.82 
1-M High
25.93 
Volume 
214.61K 
Bid
19.9
Ask
29
Day Low
19.71 
Open
20.77 
1-M Low
20.01 
Market Cap 
1.38B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 22.36 
20-SMA 22.74 
50-SMA -- 
52-W High 25.93 
52-W Low 17.2201 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.85/--
Enterprise Value
1.38B
Balance Sheet
Book Value Per Share
-4.16
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
VTGNVistagen Therapeutics, Inc.0.3684+0.117+46.54%-- 
EDVAEndovia Health Sciences Inc0.2051-0.0255-11.06%-- 
ONCOOnconetix Inc.0.91+0.2269+33.22%0PE
DCOYDecoy Therapeutics Inc.3.85+0.75+24.19%0.03PE
ARTLArtelo Biosciences Inc7.31+3.16+76.14%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.